Androgen Insensitivity Syndrome
Watchlist
Retrieved
2021-01-23
Source
Trials
—
Genes
AR,
FKBP4,
SMS,
PLAT,
RSS,
MTNR1B,
LBX1,
ESR1,
LEP,
MATN1,
IL6,
EGFR,
ESR2,
ADGRG6,
PAICS,
GART,
MTHFR,
C20orf181,
IGF1,
CALM1,
F5,
TPH1,
MT2A,
AMH,
MTNR1A,
MMP3,
TSPAN33,
TP53,
TMPRSS6,
BNC2
AR,
FKBP4,
SMS,
PLAT,
RSS,
MTNR1B,
LBX1,
ESR1,
LEP,
MATN1,
IL6,
EGFR,
ESR2,
ADGRG6,
PAICS,
GART,
MTHFR,
C20orf181,
IGF1,
CALM1,
F5,
TPH1,
MT2A,
AMH,
MTNR1A,
MMP3,
TSPAN33,
TP53,
TMPRSS6,
BNC2,
TNFRSF11B,
SIRT1,
NTF3,
SLC39A8,
NCOA2,
FBN1,
FBN2,
LEPR,
PYCARD,
PAX1,
PDXP,
GPER1,
GPX3,
SERPINE1,
TIMP2,
SHBG,
BRD2,
TGFB1,
SULT1E1,
MIR494,
VDR,
SRY,
STS,
VEGFA,
BDNF,
MIR15A,
EOS,
TP63,
ADIPOQ,
CST3,
IS1,
PITX1,
SOCS3,
POC5,
PON1,
CTNNB1,
PROM1,
KAT7,
GPR50,
PDAP1,
SIRT5,
TUSC2,
PAPOLA,
NDRG1,
TXN,
ADAMTS13,
MSC,
MRPS30,
AKR1C3,
CHL1,
BEST1,
VWF,
MYBBP1A,
USP8,
SMUG1,
UXT,
TNFSF11,
ASAP2,
GDF15,
AANAT,
TMEFF2,
MIR145,
DPP9,
NLRP3,
OCIAD2,
HJV,
NEAT1,
C17orf67,
SPATA21,
MIRLET7I,
MIR126,
MIR130A,
MIR134,
MIR183,
HECTD1,
MIR185,
MIR191,
MIR192,
MIR222,
MIR93,
PALM2AKAP2,
MT1IP,
MIR675,
CDKN2B-AS1,
MIR4300,
OCLN,
ADGRG7,
IL17RC,
DOT1L,
SPRY4,
SETBP1,
CNTNAP2,
PELP1,
CD274,
TBX21,
ASAP1,
ADIPOR1,
APH1A,
CLEC1B,
TNF,
MTPAP,
LAPTM4B,
SOX6,
MIB1,
PCDH10,
MIER1,
MID1IP1,
SOX17,
NUCKS1,
AHNAK,
IRX1,
FUZ,
VANGL1,
HSD17B7,
PSMD4,
TIMP1,
DLST,
CLTC,
COL4A2,
COL11A1,
COL11A2,
COMP,
MAP3K8,
CREBBP,
CRP,
CYP2C19,
DBP,
DMD,
CHI3L1,
DPP4,
DUSP2,
EPO,
F2,
F3,
FGFR3,
FGR,
FN1,
NR5A1,
GAD1,
CLU,
CDKN2A,
THRSP,
ASL,
ACP3,
ACTB,
ADRA1D,
ALB,
APC,
APOD,
APOE,
ARF6,
ARG1,
ARSF,
ATP2A2,
CDH13,
ATP2B4,
BGLAP,
BMP4,
BTF3P11,
CALCA,
CALM2,
CALM3,
CASP3,
RUNX2,
CD38,
GC,
GHSR,
MSH6,
ABO,
MT1L,
MT1X,
NRGN,
REG3A,
PAX3,
PBX1,
PLG,
PMCH,
MAPK7,
PSD,
RARB,
HDAC2,
PRPH2,
S100A12,
SFPQ,
SRSF1,
ITSN1,
SLC4A1,
SOX9,
SRD5A2,
STAT4,
TGM2,
MT1M,
MT1JP,
MT1H,
MT1G,
HGF,
HOXA10,
HSPG2,
IGFBP7,
IL1A,
IL1B,
IL5,
IL10,
ITGA2B,
KLK1,
KRAS,
LCN2,
LGALS1,
LGALS3,
LRPAP1,
KITLG,
MKI67,
MT1A,
MT1B,
MT1E,
MT1F,
H3P10
Drugs
—
Registered!
A disorder of sex development (DSD) characterized by the presence of female external genitalia, ambiguous genitalia or variable defects in virilization in a 46,XY individual with absent or partial responsiveness to age-appropriate levels of androgens. It comprises two clinical subgroups: complete AIS (CAIS) and partial AIS (PAIS).